1. 408OSitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL. (23rd October 2018) Authors: Bazhenova, L; Carvajal, R D; Cho, B C; Eaton, K; Goel, S; Heist, R S; Ingham, M; Wang, D; Werner, T; Neuteboom, S; Potvin, D; Chen, I; Christensen, J; Chao, R; Alva, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗